| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Pazopanib hydrochloride (JAN/USAN); Votrient (TN) | ||||||||
| Product | VOTRIENT (Novartis Pharmaceuticals Corporation) | ||||||||
| Formula | C21H23N7O2S. HCl | ||||||||
| Exact mass | 473.1401 | ||||||||
| Mol weight | 473.979 | ||||||||
| Structure |  | ||||||||
| Class | Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor | ||||||||
| Remark |
| ||||||||
| Efficacy | Antineoplastic, Receptor tyrosine kinase inhibitor | ||||||||
| Disease | Renal cell carcinoma [DS:H00021] Soft tissue sarcoma [DS:H02427] | ||||||||
| Target | PDGFR [HSA:5156 5159] [KO:K04363 K05089] VEGFR1 (FLT1) [HSA:2321] [KO:K05096] VEGFR2 (KDR) [HSA:3791] [KO:K05098] VEGFR3 (FLT4) [HSA:2324] [KO:K05097] KIT (CD117) [HSA:3815] [KO:K05091] | ||||||||
| Pathway |
| ||||||||
| Interaction | |||||||||
| Structure map |
| ||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EX Other protein kinase inhibitors L01EX03 Pazopanib D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Pazopanib D05380 Pazopanib hydrochloride (JAN/USAN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D05380 Pazopanib hydrochloride (JAN/USAN) Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor D05380 Pazopanib hydrochloride Target-based classification of drugs [BR:br08310] Protein kinases Receptor tyrosine kinases (RTK) PDGFR family PDGFR D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US> KIT (CD117) D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US> VEGFR family VEGFR1 (FLT1) D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US> VEGFR2 (KDR) D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US> VEGFR3 (FLT4) D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D05380 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D05380 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D05380 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D05380 Pharmacogenomic biomarkers [br08341.html] Polymorphisms and mutations affecting drug response D05380 | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 32 1 C8x C 8.1900 -18.2000 2 C8y C 8.1900 -19.6000 3 C8y C 9.4024 -20.3000 4 C8x C 10.6149 -19.6000 5 C8y C 10.6149 -18.2000 6 C8x C 9.4024 -17.5000 7 N5x N 13.0397 -19.6000 8 C8y C 13.0397 -18.2000 9 N1b N 11.8273 -17.5000 10 C8x C 14.2522 -20.3000 11 C8x C 15.4646 -19.6000 12 C8y C 15.4646 -18.2000 13 N5x N 14.2522 -17.5000 14 N1c N 16.6811 -17.4977 15 C8y C 17.8786 -18.1892 16 C1a C 16.6811 -16.1002 17 C1a C 6.9776 -20.3000 18 S4a S 9.4024 -21.6998 19 N1a N 9.4024 -23.0998 20 O3c O 7.9800 -21.6998 21 O3c O 10.7800 -21.6998 22 C8x C 17.8787 -19.5997 23 C8x C 19.0911 -20.2996 24 C8y C 20.3035 -19.5996 25 C8y C 20.3035 -18.1891 26 C8x C 19.0910 -17.4892 27 C8y C 21.6450 -20.0354 28 N4y N 22.4741 -18.8942 29 N5x N 21.6449 -17.7532 30 C1a C 23.8700 -18.8942 31 C1a C 22.0716 -21.3485 32 X Cl 22.1900 -23.9400 BOND 34 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 7 8 1 8 8 9 1 9 5 9 1 10 7 10 2 11 10 11 1 12 11 12 2 13 12 13 1 14 8 13 2 15 12 14 1 16 14 15 1 17 14 16 1 18 2 17 1 19 3 18 1 20 18 19 1 21 18 20 2 22 18 21 2 23 15 22 1 24 22 23 2 25 23 24 1 26 24 25 1 27 25 26 1 28 15 26 2 29 24 27 2 30 27 28 1 31 28 29 1 32 25 29 2 33 28 30 1 34 27 31 1 |